The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions

Verghese Mathew, Diane E. Grill, Christopher G. Scott, J. Aaron Grantham, Henry H. Ting, Kirk N. Garratt, David Holmes

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

OBJECTIVES: The purpose of this study was to evaluate the effect of abciximab use on clinical outcome in aortocoronary vein graft interventions. BACKGROUND: Although large randomized trials have demonstrated a significant benefit of abciximab use in the setting of percutaneous coronary interventions, there is relatively little data with respect to the use of this agent in percutaneous vein graft interventions. METHODS: Three hundred and forty-three patients were identified; 210 undergoing vein graft intervention without abciximab and 133 patients with abciximab. RESULTS: There were differences in baseline clinical and angiographic characteristics between the two groups; advanced age, unstable angina, older vein grafts and thrombus containing lesions were relatively common in both groups. Angiographic and procedural success rates were similar with or without the use of abciximab (89% vs. 92%, p = 0.15, and 85% vs. 91%, p = 0.12, respectively). The in-hospital composite end point of death/Q-wave myocardial infarction (QWMI)/repeat revascularization was similar between the two groups. Utilizing statistical modeling to adjust for baseline differences between the groups, abciximab use did not influence the cumulative long-term composite end point of death/MI/repeat revascularization. CONCLUSIONS: This study demonstrates that in this relatively high-risk population undergoing aortocoronary vein graft interventions, the administration of abciximab periprocedurally does not appear to reduce major adverse clinical events.

Original languageEnglish (US)
Pages (from-to)1163-1169
Number of pages7
JournalJournal of the American College of Cardiology
Volume34
Issue number4
DOIs
StatePublished - Oct 1999

Fingerprint

Veins
Transplants
Unstable Angina
Percutaneous Coronary Intervention
abciximab
Thrombosis
Myocardial Infarction
Population

ASJC Scopus subject areas

  • Nursing(all)

Cite this

The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. / Mathew, Verghese; Grill, Diane E.; Scott, Christopher G.; Aaron Grantham, J.; Ting, Henry H.; Garratt, Kirk N.; Holmes, David.

In: Journal of the American College of Cardiology, Vol. 34, No. 4, 10.1999, p. 1163-1169.

Research output: Contribution to journalArticle

Mathew, Verghese ; Grill, Diane E. ; Scott, Christopher G. ; Aaron Grantham, J. ; Ting, Henry H. ; Garratt, Kirk N. ; Holmes, David. / The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. In: Journal of the American College of Cardiology. 1999 ; Vol. 34, No. 4. pp. 1163-1169.
@article{f92de0a235fe42f9bba862878f8dd0a4,
title = "The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions",
abstract = "OBJECTIVES: The purpose of this study was to evaluate the effect of abciximab use on clinical outcome in aortocoronary vein graft interventions. BACKGROUND: Although large randomized trials have demonstrated a significant benefit of abciximab use in the setting of percutaneous coronary interventions, there is relatively little data with respect to the use of this agent in percutaneous vein graft interventions. METHODS: Three hundred and forty-three patients were identified; 210 undergoing vein graft intervention without abciximab and 133 patients with abciximab. RESULTS: There were differences in baseline clinical and angiographic characteristics between the two groups; advanced age, unstable angina, older vein grafts and thrombus containing lesions were relatively common in both groups. Angiographic and procedural success rates were similar with or without the use of abciximab (89{\%} vs. 92{\%}, p = 0.15, and 85{\%} vs. 91{\%}, p = 0.12, respectively). The in-hospital composite end point of death/Q-wave myocardial infarction (QWMI)/repeat revascularization was similar between the two groups. Utilizing statistical modeling to adjust for baseline differences between the groups, abciximab use did not influence the cumulative long-term composite end point of death/MI/repeat revascularization. CONCLUSIONS: This study demonstrates that in this relatively high-risk population undergoing aortocoronary vein graft interventions, the administration of abciximab periprocedurally does not appear to reduce major adverse clinical events.",
author = "Verghese Mathew and Grill, {Diane E.} and Scott, {Christopher G.} and {Aaron Grantham}, J. and Ting, {Henry H.} and Garratt, {Kirk N.} and David Holmes",
year = "1999",
month = "10",
doi = "10.1016/S0735-1097(99)00329-0",
language = "English (US)",
volume = "34",
pages = "1163--1169",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions

AU - Mathew, Verghese

AU - Grill, Diane E.

AU - Scott, Christopher G.

AU - Aaron Grantham, J.

AU - Ting, Henry H.

AU - Garratt, Kirk N.

AU - Holmes, David

PY - 1999/10

Y1 - 1999/10

N2 - OBJECTIVES: The purpose of this study was to evaluate the effect of abciximab use on clinical outcome in aortocoronary vein graft interventions. BACKGROUND: Although large randomized trials have demonstrated a significant benefit of abciximab use in the setting of percutaneous coronary interventions, there is relatively little data with respect to the use of this agent in percutaneous vein graft interventions. METHODS: Three hundred and forty-three patients were identified; 210 undergoing vein graft intervention without abciximab and 133 patients with abciximab. RESULTS: There were differences in baseline clinical and angiographic characteristics between the two groups; advanced age, unstable angina, older vein grafts and thrombus containing lesions were relatively common in both groups. Angiographic and procedural success rates were similar with or without the use of abciximab (89% vs. 92%, p = 0.15, and 85% vs. 91%, p = 0.12, respectively). The in-hospital composite end point of death/Q-wave myocardial infarction (QWMI)/repeat revascularization was similar between the two groups. Utilizing statistical modeling to adjust for baseline differences between the groups, abciximab use did not influence the cumulative long-term composite end point of death/MI/repeat revascularization. CONCLUSIONS: This study demonstrates that in this relatively high-risk population undergoing aortocoronary vein graft interventions, the administration of abciximab periprocedurally does not appear to reduce major adverse clinical events.

AB - OBJECTIVES: The purpose of this study was to evaluate the effect of abciximab use on clinical outcome in aortocoronary vein graft interventions. BACKGROUND: Although large randomized trials have demonstrated a significant benefit of abciximab use in the setting of percutaneous coronary interventions, there is relatively little data with respect to the use of this agent in percutaneous vein graft interventions. METHODS: Three hundred and forty-three patients were identified; 210 undergoing vein graft intervention without abciximab and 133 patients with abciximab. RESULTS: There were differences in baseline clinical and angiographic characteristics between the two groups; advanced age, unstable angina, older vein grafts and thrombus containing lesions were relatively common in both groups. Angiographic and procedural success rates were similar with or without the use of abciximab (89% vs. 92%, p = 0.15, and 85% vs. 91%, p = 0.12, respectively). The in-hospital composite end point of death/Q-wave myocardial infarction (QWMI)/repeat revascularization was similar between the two groups. Utilizing statistical modeling to adjust for baseline differences between the groups, abciximab use did not influence the cumulative long-term composite end point of death/MI/repeat revascularization. CONCLUSIONS: This study demonstrates that in this relatively high-risk population undergoing aortocoronary vein graft interventions, the administration of abciximab periprocedurally does not appear to reduce major adverse clinical events.

UR - http://www.scopus.com/inward/record.url?scp=0033213390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033213390&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(99)00329-0

DO - 10.1016/S0735-1097(99)00329-0

M3 - Article

C2 - 10520807

AN - SCOPUS:0033213390

VL - 34

SP - 1163

EP - 1169

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 4

ER -